On Nov 15, 2017, Court of appeal for the federal circuit in a non-precedential opinion affirmed the decision of paten trial & appellate board (PTAB) which found formulation patent of Teduglutide (Gattex) invalid. Previously PTAB found NPS pharmaceutical’s U.S. Patent Number 7,056,886 invalid under obviousness in two IPR proceedings (IPR2015-00990 & IPR2015-01093).

US’886 claims GLP-2 (teduglutide) composition with histidine, phosphate buffer &  mannitol /sucrose. PTAB in its decision held that use of histidine & mannitol was well known in protein formulation and experimentation needed to confirm successful application with GLP-2 analog was nothing more than routine practice.